APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
86 Views
Hanmi Pharm (128940 KS): Why Shares Plunge Despite Record High 2Q Operating Profit; What Lies Ahead
Hanmi Pharm outlicenses HM1732, next-generation muscle mass preserving obesity drug candidate with first-in-class potential, to Genentech for a...
121 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
872 Views
HK Inno.N (195940 KS): Modest Show In 1Q26; All Eyes on Maiden US Approval; Strengthening Pipeline
HK inno reports 1Q26 result, with key parameters showing improvement compared to year-ago period. The company is expected to maintain momentum,...
426 Views
APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia
Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...
103 Views